Sattva S Neelapu Selected Research

Mitoxantrone (Novantrone)

1/2021	Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma.
1/2017	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
11/2016	Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sattva S Neelapu Research Topics

Disease

80	Neoplasms (Cancer) 12/2023 - 09/2002
55	B-Cell Lymphoma (Lymphoma, B Cell) 04/2024 - 08/2012
47	Lymphoma (Lymphomas) 11/2023 - 12/2004
36	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2024 - 03/2004
17	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2024 - 09/2002
15	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2023 - 08/2012
14	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2023 - 01/2007
13	Cytokine Release Syndrome 01/2023 - 01/2017
8	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 12/2010
7	Inflammation (Inflammations) 01/2023 - 11/2009
7	cell-associated neurotoxicity 01/2023 - 06/2019
7	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 11/2009
5	Melanoma (Melanoma, Malignant) 12/2023 - 02/2008
5	Disease Progression 12/2023 - 06/2009
5	Leukemia 01/2022 - 12/2017
4	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2020 - 08/2012
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019 - 09/2002
4	Multiple Myeloma 01/2016 - 09/2002
3	Exanthema (Rash) 11/2023 - 11/2015
3	Breast Neoplasms (Breast Cancer) 02/2023 - 12/2021
3	Communicable Diseases (Infectious Diseases) 01/2023 - 02/2008
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 02/2016
2	Cytopenia 01/2023 - 10/2021
2	Arthritis (Polyarthritis) 12/2022 - 01/2019
2	Sepsis (Septicemia) 01/2021 - 01/2019
2	Acute Lung Injury 01/2021 - 01/2019
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020 - 01/2019
2	Pneumonia (Pneumonitis) 01/2020 - 10/2019
2	Colitis 10/2019 - 01/2019

Drug/Important Bio-Agent (IBA)

44	Chimeric Antigen ReceptorsIBA 04/2024 - 01/2017
33	axicabtagene ciloleucelIBA 03/2024 - 01/2017
29	Rituximab (Mabthera)FDA Link 11/2023 - 06/2006
22	AntigensIBA 11/2023 - 09/2002
20	VaccinesIBA 12/2021 - 09/2002
10	CytokinesIBA 11/2023 - 12/2004
10	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2023 - 02/2004
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2002
10	Immunoglobulins (Immunoglobulin)IBA 01/2019 - 09/2002
8	Biomarkers (Surrogate Marker)IBA 12/2023 - 09/2015
8	Lenalidomide (CC 5013)FDA Link 11/2023 - 07/2012
8	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2014
7	fludarabineIBA 01/2022 - 02/2004
5	ibrutinibIBA 11/2023 - 02/2016
5	Monoclonal AntibodiesIBA 01/2022 - 01/2014
5	Cancer VaccinesIBA 01/2018 - 09/2002
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2016 - 06/2006
5	EpitopesIBA 01/2016 - 06/2006
5	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 07/2011 - 06/2006
4	RNA (Ribonucleic Acid)IBA 11/2023 - 01/2017
4	Bendamustine Hydrochloride FDA Link 10/2023 - 09/2013
4	tisagenlecleucelIBA 01/2022 - 01/2018
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 02/2007
4	ChemokinesIBA 01/2018 - 10/2004
4	Peptides (Polypeptides)IBA 01/2016 - 03/2004
4	Immunoglobulin Idiotypes (Idiotype, Immunoglobulin)IBA 09/2011 - 01/2007
3	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2023 - 05/2012
3	Vincristine (Oncovin)FDA LinkGeneric 11/2023 - 03/2015
3	Therapeutic UsesIBA 02/2023 - 01/2018
3	InterferonsIBA 01/2023 - 01/2016
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 01/2019
3	pembrolizumabIBA 01/2022 - 09/2015
3	EnzymesIBA 01/2022 - 11/2009
3	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2021 - 01/2020
3	Dexamethasone (Maxidex)FDA LinkGeneric 01/2021 - 11/2015
3	ibritumomab tiuxetan (Zevalin)FDA Link 01/2021 - 06/2012
3	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2021 - 11/2016
3	Phosphotransferases (Kinase)IBA 01/2021 - 10/2012
3	Histone Deacetylases (Histone Deacetylase)IBA 11/2020 - 11/2009
3	Methotrexate (Mexate)FDA LinkGeneric 10/2018 - 06/2008
3	DNA VaccinesIBA 01/2018 - 11/2007
3	AntibodiesIBA 01/2018 - 01/2014
3	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2016 - 09/2011
2	brexucabtagene autoleucelIBA 01/2024 - 10/2023
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 11/2023 - 01/2020
2	Prednisone (Sone)FDA LinkGeneric 11/2023 - 03/2015
2	Docetaxel (Taxotere)FDA Link 02/2023 - 01/2023
2	plerixafor FDA Link 02/2023 - 01/2023
2	Trastuzumab (Herceptin)FDA Link 02/2023 - 01/2023
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 01/2018
2	CD40 Ligand (CD40L)IBA 01/2021 - 06/2013
2	MTOR InhibitorsIBA 11/2020 - 12/2010
2	Histone Deacetylase InhibitorsIBA 11/2020 - 11/2009
2	Bleomycin (Blenoxane)FDA LinkGeneric 07/2020 - 05/2012
2	AnthracyclinesIBA 01/2019 - 03/2015
2	NivolumabIBA 01/2019 - 09/2015
2	Pentostatin (Nipent)FDA LinkGeneric 01/2019 - 06/2015
2	idelalisibIBA 01/2017 - 05/2015
2	Bortezomib (Velcade)FDA Link 02/2016 - 01/2013
2	Interleukin-2 (IL2)IBA 01/2016 - 06/2007
2	liposomal doxorubicin (Doxil)FDA Link 11/2015 - 03/2015
2	pidilizumabIBA 09/2015 - 01/2014

Therapy/Procedure

77	Therapeutics 03/2024 - 09/2005
23	Drug Therapy (Chemotherapy) 04/2024 - 12/2004
23	Immunotherapy 12/2023 - 09/2002
9	Radiotherapy 10/2021 - 10/2014
6	Stem Cell Transplantation 01/2023 - 06/2008
4	Transplantation 01/2023 - 11/2010
2	Critical Care (Surgical Intensive Care) 01/2022 - 01/2021
2	Cell Transplantation 01/2021 - 12/2019
2	Combined Modality Therapy 01/2021 - 07/2020